期刊文献+

特异性环氧化酶-Ⅱ抑制药——罗非昔布 被引量:1

下载PDF
导出
摘要 综述非甾体抗炎药———罗非昔布的药理作用特点和临床应用。研究表明 ,罗非昔布可有效地抑制环氧化酶 Ⅱ ,能够减少脂多糖诱导的前列腺素E2 的合成 ,而对血小板或胃粘膜中的血栓素B2 的合成无明显影响 ;临床应用显示 ,罗非昔布对骨关节炎及剧痛的疗效较好 。
作者 崔志平
出处 《医药导报》 CAS 2002年第6期379-380,共2页 Herald of Medicine
  • 相关文献

参考文献10

  • 1Day R,Morrison B,Luza A,et al.A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis[].Archives of Internal Medicine.2000
  • 2Morrison B W,Daniels S E,Kotey P,et al.Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: a randomized controlled trial[].Obstetrics and Gynecology.1999
  • 3Geba G P,Polis A B,Dixon M E,et al.Rofecoxib results in superior clinical response compared to nabumetone in the treatment of osteoarthritis[].Arthritis and Rheumatism.1999
  • 4Laine L,Harper S,Simon T,et al.A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis[].Gastroenterology.1999
  • 5Watson D J,Harper S E,Zhao P L,et al.Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis[].Archives of Internal Medicine.2000
  • 6Saag K,Van Der Heijde D,Fisher C,et al.Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs: a 6-week and a 1-year trial in patients with osteoarthritis[].Archives of Family Medicine.2000
  • 7Lanza F L,Rack M F,Simon T J,et al.Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen[].Alimentary Pharmacology and Therapeutics.1999
  • 8Reicin A S,Brown J,Jove M,et al.The COX-2 specific inhibitor,rofecoxib, was effective in the treatment of postorthopedic surgical pain[].Arthritis and Rheumatism.1999
  • 9Van Hecken A,Depre M,Ehrich E,et al.Demonstration of specific COX-2 inhibition by MK-966 in human with supratherapeutic doses[].Clinical Pharmacology and Therapeutics.1999
  • 10Daniels B,Seidenberg B.Cardiovascular safety profile of rofecoxib in controlled clinical trials[].Arthritis and Rheumatism.1999

同被引文献2

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部